Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Surgery Partners, Inc. (SGRY)

Surgery Partners Q2 revenue rises 2.7% to $848.9 million; net loss widens

Mixed Impact 3 of 5 earnings Written later

Surgery Partners reported second-quarter 2026 revenue up 2.7% to $848.9 million, but its net loss attributable to the company widened to $15.0 million from $2.5 million a year earlier, and Adjusted EBITDA fell to $125.2 million from $129.0 million. The company reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance, excluding the pending Idaho Falls divestiture.

Key points

  • Revenue rose 2.7% to $848.9 million; same-facility revenues rose 5.0% and same-facility cases rose 0.3%.
  • Net loss attributable to Surgery Partners was $15.0 million, or $0.12 per share, versus a $2.5 million loss in Q2 2025.
  • Adjusted EBITDA was $125.2 million, compared with $129.0 million in Q2 2025.
  • Full-year 2026 guidance reaffirmed: revenue of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the Idaho Falls divestiture.

The filing

CompanySurgery Partners, Inc. (SGRY)
Form8-K, current report
Filed with the SECAug 10, 2026, 7:32 AM ET
Accession number0001638833-26-000074

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.